![Shuichi Kanazashi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shuichi Kanazashi
Director/Miembro de la Junta en SATSUMA PHARMACEUTICALS, INC. .
Cargos activos de Shuichi Kanazashi
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Ventas & Marketing | 01/04/2020 | - |
Director/Miembro de la Junta | 01/06/2014 | 29/06/2016 | |
Corporate Officer/Principal | 01/04/2014 | 01/04/2020 | |
SATSUMA PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 08/06/2023 | - |
Historial de carrera de Shuichi Kanazashi
Antiguos cargos conocidos de Shuichi Kanazashi.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
UMN PHARMA INC. | Fundador | 20/04/2004 | 01/03/2012 |
Presidente | 01/01/2005 | 01/03/2012 | |
SONY GROUP CORPORATION | Corporate Officer/Principal | - | - |
Nippon Roche KK
![]() Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Corporate Officer/Principal | - | - |
Formación de Shuichi Kanazashi.
Kyoto University | Doctorate Degree |
Estadísticas
Internacional
Japón | 6 |
Estados Unidos | 2 |
Operativa
Corporate Officer/Principal | 3 |
Director/Board Member | 2 |
Founder | 1 |
Sectorial
Health Technology | 4 |
Consumer Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
SONY GROUP CORPORATION | Electronic Technology |
Empresas privadas | 3 |
---|---|
UMN Pharma, Inc.
![]() UMN Pharma, Inc. Pharmaceuticals: MajorHealth Technology UMN Pharma, Inc. engages in the development, manufacture, and sale of biopharmaceuticals. It operates through a following business division: Next-generation biopharmaceutical in-house development business and Biopharmaceutical contract manufacturing business. The Next-generation biopharmaceutical in-house development business engages in the research and development of next-generation logical vaccine by integrating next-generation biopharmaceutical drug substance manufacturing technology, adjuvant technology and drug delivery technology. The Biopharmaceutical contract manufacturing business offers study samples, investigational drugs, products, and various evaluation test results. The company was founded by Masahiro Michishita and Shuichi Kanazashi on April 20, 2004 and is headquartered in Akita, Japan. | Health Technology |
Nippon Roche KK
![]() Nippon Roche KK Pharmaceuticals: MajorHealth Technology Part of Roche Holding AG, Nippon Roche KK is a Japanese company that manufactures and sells pharmaceuticals. The company is based in Tokyo, Japan. Nippon Roche KK was acquired by Chugai Pharmaceutical Co., Ltd. from Roche Holding AG on October 01, 2002 for $1,613.74 million. | Health Technology |
Satsuma Pharmaceuticals, Inc.
![]() Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Shuichi Kanazashi
- Experiencia